New Director's Experience a Plus for MSU, but his Controversial Views Concern Some
By Matthew Miller,
Lansing State Journal
| 10. 06. 2012
Stephen Hsu was an unconventional choice to lead Michigan State University’s research enterprise.
A theoretical physicist by training, Hsu has done respected work on dark energy, black holes and the more esoteric reaches of particle physics, but his only experience in academic administration was a stint last year as the director of the University of Oregon’s Institute for Theoretical Science. The institute’s budget that year was just shy of $74,000.
As vice president for research and graduate studies at MSU, the position he assumed in August, Hsu is charged with setting the broad direction and expectations for a research operation that topped $400 million in expenditures in 2010. His office administers millions in internal grant money, ensures the university’s compliance with ethical and legal standards for research, leads MSU’s efforts to commercialize its research.
But Hsu has another sort of experience that MSU’s leaders found compelling: years as a Silicon Valley entrepreneur, and a successful one at that.
MSU President Lou Anna Simon said Hsu is not only “an extraordinary intellect,” but he “understands the relationship of research to economic...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Ed Cara, Gizmodo | 06.22.2025
In late May, several scientific organizations, including the International Society for Cell and Gene Therapy (ISCT), banded together to call for a 10-year moratorium on using CRISPR and related technologies to pursue human heritable germline editing. The declaration also outlined...
By Isabel van Brugen, Newsweek | 06.05.2025
A U.S.-based biotech company has unveiled a new in vitro fertilization (IVF) option that allows parents to select embryos based on genetic markers tied to health and longevity.
DNA testing and analysis company Nucleus Genomics has announced the world's first...
By Jonathan D. Grinstein, PhD, Inside Precision Medicine | 06.03.2025
On Tuesday, 307 days after he was first admitted to Children’s Hospital of Philadelphia (CHOP), KJ Muldoon went home after being successfully treated with the first personalized CRISPR gene editing therapy. KJ, who was born with a serious and...